نتائج البحث - Sanjiv Modi
- يعرض 1 - 2 نتائج من 2
-
1
Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium حسب Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas Younes, Scott E. Smith, Patrick J. Stiff, Eric P. Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes, Barbara Pro
منشور في 2010Artigo -
2
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer حسب Walter M. Stadler, David J. Vaughn, Guru Sonpavde, Nicholas J. Vogelzang, Scott T. Tagawa, Daniel P. Petrylak, Peter J. Rosen, Chia‐Chi Lin, John F. Mahoney, Sanjiv Modi, Peter P. Lee, Marc S. Ernstoff, Wu‐Chou Su, Alexander I. Spira, Korinna Pilz, Richard Vinisko, Charles Schloss, Holger Fritsch, Charles Zhao, Michael A. Carducci
منشور في 2013Artigo
أدوات البحث:
موضوعات ذات صلة
Chemotherapy
Gastroenterology
Internal medicine
Medicine
Oncology
Adverse effect
Apoptosis
Biochemistry
Biology
Clinical endpoint
Clinical trial
Cumulative incidence
Diffuse large B-cell lymphoma
Discovery and development of mTOR inhibitors
Febrile neutropenia
Follicular lymphoma
Lymphoma
Mantle cell lymphoma
Mucositis
Neutropenia
PI3K/AKT/mTOR pathway
Phases of clinical research
Progression-free survival
Progressive disease
Regimen
Surgery
Temsirolimus
Transplantation